Parameter | rhPTH(1-84) (n=134) | Conventional Therapy (n=603) | Analysis Populationa (N=737) |
---|---|---|---|
Age, mean ± SD, y | 47.9±14.22 | 49.3±16.91 | 49.1±16.45 |
Age, category, n (%), y | |||
0–17 | 3 (2.2) | 24 (4.0) | 27 (3.7) |
18–39 | 34 (25.4) | 135 (22.4) | 169 (22.9) |
40–64 | 81 (60.4) | 336 (55.7) | 417 (56.6) |
≥65 | 16 (11.9) | 108 (17.9) | 124 (16.8) |
Women, n (%) | 115 (85.8) | 472 (78.3) | 587 (79.6) |
Race, white, n (%) | 112 (83.6) | 508 (84.2) | 620 (84.1) |
BMI, mean ± SD, y | |||
<18b | 17.2±0.46 | 19.6±6.07 | 19.3±5.73 |
≥18c | 31.1±9.48 | 29.7±7.32 | 30.0±7.72 |
Primary cause of hypoparathyroidism, n (%) | |||
Surgery | 85 (63.4) | 462 (76.6) | 547 (74.2) |
Idiopathic | 12 (9.0) | 46 (7.6) | 58 (7.9) |
Genetic and autoimmune | 12 (9.0) | 44 (7.3) | 56 (7.6) |
Radiation | 0 | 1 (0.2) | 1 (0.1) |
Unknown/other/missing | 25 (18.7) | 50 (8.3) | 75 (10.2) |
Primary cause for thyroid surgery | |||
Thyroid cancer, n (%) | 37 (56.1) | 244 (60.7) | 281 (60.0) |
Duration of hypoparathyroidism, mean ± SD, yd | 9.0±10.27 | 10.3±11.53 | 10.1±11.34 |